Oliceridine (TRV130) is an opioid medication that is used for the treatment of moderate to severe acute pain in adults.

Oliceridine (TRV130) is indicated for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures. It is not indicated for at-home use.

Oliceridine (TRV130) is a μ-opioid receptor biased agonist developed by Trevena. In cell-based (in vitro) research, oliceridine elicits robust G protein signaling, with potency and efficacy similar to that of morphine, but with less β-arrestin 2 recruitment and receptor internalization. However, recent reports highlight that this might be due to its low intrinsic efficacy, rather than functional selectivity or 'G protein bias' as initially reported. In vivo, it may have fewer adverse effects (including respiratory depression and constipation) compared with morphine. In general, in vitro potency does not guarantee any clinical relevance in humans.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.